Find a study
Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.
43 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Obesity / overweight
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Testing a 52-week medicine versus placebo in adults with obstructive sleep apnea on CPAP
📍 Valley Clinical Trials · Northridge, CA · +12 more US sites · Get directions →
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.
- Obesity / overweight
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Testing how fasting and briefly stopping GLP-1 medicines changes stomach food
📍 Altasciences Clinical LA, Inc. · Cypress, CA · Get directions →
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
- Obesity / overweight
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Testing a weekly injection in people with obesity and sleep apnea to lose weight and improve sleep
📍 Dignity Health, Mercy Gilbert · Gilbert, AZ · +19 more US sites · Get directions →
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Testing a weekly under-the-skin injection to see effects on weight and diabetes markers
📍 Kailera Clinical Site · Cullman, AL · +34 more US sites · Get directions →
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
- Obesity / overweight
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Testing a weekly under-the-skin medicine to help adults with obesity lose weight
📍 South Broward Research LLC · Miramar, FL · +21 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightType 2 diabetes
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Testing different doses of a medicine for weight loss in people with obesity or overweight and type
📍 Lakeview Clinical Research · Guntersville, AL · +33 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).
- Obesity / overweight
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Testing a skin patch delivery of semaglutide versus a shot in people with obesity
📍 Celerion Clinical Research · Tempe, AZ · Get directions →
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Testing eloralintide in people with sleep apnea and obesity
📍 Cullman Clinical Trials · Cullman, AL · +22 more US sites · Get directions →
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Testing whether eloralintide helps people with obesity or overweight and type 2 diabetes lose weight
📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Testing a medicine called eloralintide in adults with obesity or overweight without type 2 diabetes
📍 MFA Clinical Research · Tuscaloosa, AL · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
- Obesity / overweight
A Study to Evaluate ALN-2232 in Participants With Obesity
Testing a weight-loss drug in people with obesity for safety and how it works
📍 Clinical Trial Site · Mount Royal, · Get directions →
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
- Obesity / overweight
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Testing the safety and how the body absorbs a nasal spray in adults with obesity
📍 Frontage Clinical Services, Inc. · Secaucus, NJ · Get directions →
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
- Obesity / overweight
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Testing a weekly injection medicine for adults with obesity and knee arthritis pain
📍 Arizona Research Center, Inc. · Phoenix, AZ · +18 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Testing how weight-loss medicines affect metabolism compared with diet
📍 Advent Health-Res Inst · Orlando, FL · +1 more US site · Get directions →
In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine.
- Obesity / overweight
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Testing an injection treatment once a week for people with obesity to help maintain weight loss
📍 Pinnacle Research Group LLC · Anniston, AL · +12 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightCrohn's / ulcerative colitis (IBD)
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Testing two medicines together to reduce ulcerative colitis symptoms and weight in adults with
📍 Digestive Health Specialists · Dothan, AL · +36 more US sites · Get directions →
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
- Obesity / overweightCrohn's / ulcerative colitis (IBD)
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Testing treatments for adults with Crohn’s disease and excess weight
📍 Digestive Health Specialists · Dothan, AL · +34 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
- Obesity / overweight
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
Testing how maridebart cafraglutide changes how birth control pills are absorbed
📍 Fortrea Clinical Research Unit - Daytona Beach · Daytona Beach, FL · +2 more US sites · Get directions →
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
- Obesity / overweight
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Testing injections once a week to help adults with obesity and type 2 diabetes lose weight
📍 Univ of Alabama Birmingham · Birmingham, AL · +14 more US sites · Get directions →
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweight
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Testing how well CagriSema and cagrilintide help children with obesity lose weight
📍 Neighborhood Healthcare · Escondido, CA · +33 more US sites · Get directions →
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study.
- Obesity / overweight
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Testing a once-weekly under-the-skin injection for weight loss in adults with obesity or overweight
📍 Kailera Clinical Site · Anniston, AL · +22 more US sites · Get directions →
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
- Obesity / overweight
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Testing tirzepatide with healthy diet and exercise for teens with obesity
📍 Children's Hospital Los Angeles · Los Angeles, CA · +13 more US sites · Get directions →
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
- Obesity / overweight
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Studying how teens’ bodies respond to weight-loss surgery, with and without semaglutide
📍 Childrens Hospital Colorado · Aurora, CO · Get directions →
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone.
- Obesity / overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Testing retatrutide to help people with obesity and chronic low back pain
📍 MD First Research - Chandler · Chandler, AZ · +24 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
- Obesity / overweightHeart / cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity
📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people
📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).
- Obesity / overweightType 2 diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Testing different doses of CagriSema and semaglutide for weight loss in people with obesity, with or
📍 Uni of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants.
- Obesity / overweightHeart / cardiovascular disease
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight
📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.
- Obesity / overweight
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Testing a weekly under-the-skin medicine to help people with excess weight and sleep apnea lose
📍 Artemis Insitute for Clin Res · San Diego, CA · +16 more US sites · Get directions →
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the skin once a week.
- Obesity / overweightHigh blood pressureCOPD (chronic lung disease)
Feasibility of Semaglutide in Advanced Lung Disease
Testing whether semaglutide can be given safely to people with advanced lung disease
📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.
- Obesity / overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Testing how safe and well people with obesity do after switching to a new diabetes-like weight drug
📍 Cahaba Research, Inc. · Pelham, AL · +39 more US sites · Get directions →
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Obesity / overweight
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Testing how safely cagrilintide is tolerated in people with obesity who can’t tolerate GLP-1
📍 Diablo Clinical Research, Inc. · Walnut Creek, CA · +10 more US sites · Get directions →
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it).
- Obesity / overweight
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Testing whether semaglutide weight loss treatment affects atrial fibrillation
📍 The University of Arizona College of Medicine- Phoenix · Phoenix, AZ · +1 more US site · Get directions →
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
- Obesity / overweight
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Testing an injection once a week to see if it helps people with excess body weight and knee
📍 Neighborhood Healthcare · Escondido, CA · +18 more US sites · Get directions →
This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week.
- Dementia / Alzheimer's
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Testing a treatment with IL-2 and semaglutide in people with Alzheimer's
📍 Houston Methodist Research Institute · Houston, TX · Get directions →
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Obesity / overweightHeart / cardiovascular disease
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Testing how semaglutide works in people with heart failure and obesity
📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.
- Obesity / overweightHigh blood pressure
Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study
Testing how an egg-derived peptide affects health in people with obesity and high blood pressure
📍 University of Alberta · Edmonton, Alberta · Get directions →
Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides.
- Obesity / overweight
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Testing a weekly under-the-skin shot for obesity on body weight
📍 Kailera Clinical Site · Glendale, AZ · +26 more US sites · Get directions →
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
- Obesity / overweightHigh blood pressure
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
Studying what happens to heart health and weight after stopping a weight-loss drug in people with
📍 Leadership Sinai Centre for Diabetes · Toronto, Ontario · Get directions →
Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide.
- Obesity / overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Testing a medicine with GLP-1 and GIP effects at different doses for weight control in adults
📍 Pinnacle Research Group · Anniston, AL · +30 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
- Obesity / overweight
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Testing how safe and effective eloralintide is for knee pain in adults with obesity
📍 AMR Clinical · Mobile, AL · +37 more US sites · Get directions →
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain.
- Obesity / overweight
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Testing eloralintide versus placebo for persistent obesity and safety
📍 Birmingham Clinical Research · Birmingham, AL · +39 more US sites · Get directions →
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
- Obesity / overweight
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Testing a diabetes-related injection to help girls and women with obesity and PCOS restore ovulation
📍 University of Colorado Anschutz/Children's Hospital Colorado Aurora · Aurora, CO · Get directions →
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.